All terms
National Medical Products Administration
China's regulatory authority for drugs, medical devices, and cosmetics.
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed September 19, 2026
Definition
NMPA (formerly CFDA) regulates the registration, manufacture, import, and post-market surveillance of medical devices in mainland China through a three-class risk-based framework. Under China's Regulations on the Supervision and Administration of Medical Devices (State Council Order No. 739), devices are classified into Class I, II and III. Class I products are filed, while Class II and III products need registration, with imported Class II and III devices registered with the NMPA. Registration often requires type testing in Chinese accredited labs and clinical evaluation, which can sometimes be met through equivalence or exemption lists. What the regulation says
The National Medical Products Administration (NMPA) operates under the direct leadership of the State Administration for Market Regulation (SAMR) and is responsible for drug (including active pharmaceutical ingredients, excipients), medical device, and cosmetic regulation in mainland China. The NMPA's regulatory framework for medical devices is outlined in various NMPA orders and decrees, such as NMPA Order 659, which details medical device registration and filing administration. This framework dictates requirements for product registration, clinical evaluation, and post-market surveillance.What this means in practice
Most Class II and III devices require in-country clinical evaluation or trials, type testing at NMPA-designated labs, and a local agent. Recent reforms have introduced an innovative-device fast track and accept some overseas data.Examples
- A European MedTech company seeking to market its Class II surgical robot in China must first go through NMPA type testing at a designated NMPA laboratory and appoint a local legal agent.
- A manufacturer of a novel Class III implantable device applies for the NMPA innovative device fast track, demonstrating its significant clinical benefit and technological breakthrough compared to existing options.
- A US-based company selling diagnostic reagents in China undergoes an NMPA post-market surveillance audit, where the NMPA reviews its quality management system and compliance with Chinese regulations.
Common pitfalls
- •A common pitfall is underestimating the need for local representation and testing, which are often mandatory for foreign manufacturers.
- •Manufacturers sometimes misunderstand the specific criteria for the "innovative device" fast track, leading to incorrect application strategies.
- •Failing to keep up with frequently updated NMPA regulations and guidance documents can result in compliance issues.
- •Assuming that international certifications or clinical data are always directly accepted without NMPA-specific review or bridging studies is a frequent mistake.
- •Inadequate preparation for NMPA on-site audits and inspections can lead to delays or non-compliance findings.
Frequently asked questions
The NMPA uses a three-class risk-based classification system, similar to many other regulatory bodies. Class I devices pose low risk, Class II devices pose medium risk, and Class III devices pose high risk to patients and users.
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsMore in Regulatory
· Same categoryRegulatory
510(k) Premarket Notification(510(k))
FDA submission demonstrating a device is substantially equivalent to a legally marketed predicate.
Regulatory
510(k) Summary vs 510(k) Statement
Two alternative disclosure mechanisms in a 510(k) submission, a Summary is public on FDA's website; a Statement promises to share Safety & Effectiveness info on request.
Regulatory
513(g) Request for Information(513(g))
Formal mechanism to ask FDA whether a product is a device and, if so, its likely classification.
Regulatory
Abbreviated 510(k)
510(k) variant that relies on FDA guidance, special controls, or recognized consensus standards.
Cited by
Where this term appears across MedTech Terms.
Ecosystems (2)
Latest in MedTech
Sources
3 sourcesSources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.
Tier 2Regulator guidance and consensus· 3
Link health: 3 verified· last checked 2026-06-20
NMPA·1FDA·1European Commission·1
- 1NMPA English portalTier 2 VerifiedNMPAenglish.nmpa.gov.cn
- 2FDA - Medical DevicesTier 2 VerifiedFDAfda.gov
- 3European Commission - Medical DevicesTier 2 VerifiedEuropean Commissionhealth.ec.europa.eu
Inline markers like [1] jump to the matching reference above.